What Does a FibroScan Score Over 10.5 kPa Mean for PSC?
At a Glance
For patients with Primary Sclerosing Cholangitis, a FibroScan score over 10.5 kPa indicates advanced liver scarring or fibrosis. This level of stiffness means your care team will closely monitor you for complications like portal hypertension and recommend routine screenings to protect your health.
If your doctor told you your FibroScan score is over 10.5 kPa, it means that the test has detected advanced scarring (fibrosis) in your liver, which may be approaching or at the stage of cirrhosis. A FibroScan (also called transient elastography) is a non-invasive ultrasound-like test that measures liver stiffness to estimate the amount of scarring [1][2]. In Primary Sclerosing Cholangitis (PSC), a score above 10.5 kPa places you in a higher risk category for liver-related complications and changes how closely your medical team will need to monitor you [3][4].
How FibroScan Measures Liver Damage in PSC
As PSC damages the bile ducts, it causes inflammation and progressive scarring in the liver tissue. Healthy liver tissue is soft, while scarred tissue becomes stiff [1]. The FibroScan device sends a mild sound wave through your liver and measures how fast it travels; the faster the wave, the stiffer the liver. The result is given in kilopascals (kPa).
While specific cut-offs can vary slightly depending on the study, research in PSC generally shows that scores around 8.6 to 9.6 kPa suggest advanced fibrosis, and scores approaching 13.7 to 14.0 kPa suggest cirrhosis [5][1]. Therefore, a score over 10.5 kPa indicates significant, advanced fibrosis that requires careful management [3].
What This Means for Your Health
Having a score over 10.5 kPa means your liver has lost some of its flexibility, which can make it harder for blood to flow through it. This can lead to portal hypertension (high blood pressure in the vein that carries blood to the liver) [6].
Because of this risk, your doctor will likely recommend more intensive monitoring for complications associated with advanced fibrosis and cirrhosis [4]. This may include:
- Screening for varices: Portal hypertension can cause veins in your esophagus or stomach to become swollen (varices) [6]. Your doctor may recommend an endoscopy to check for these. However, if your FibroScan is under 20 kPa and your blood platelet count is normal (above 150), your risk of needing treatment for varices is currently very low [7].
- Proactive cancer screening: Because advanced scarring increases the risk of liver cancer (hepatocellular carcinoma) and bile duct cancer (cholangiocarcinoma), your doctor will likely schedule regular ultrasounds or MRIs [8][9]. These routine screenings are proactive safety measures designed to catch any changes as early as possible—they are a standard part of care, not a guarantee that you will develop cancer.
- Combining tests for better accuracy: FibroScan is just one tool. Your doctor might combine these results with an MRI (such as Magnetic Resonance Elastography, or MRE) or blood tests to get a clearer picture of your exact risk level [3][10].
Can the Score Fluctuate?
Yes. It is important to know that FibroScan scores can be temporarily elevated by factors other than permanent scarring. In PSC, active inflammation or blockages in your bile ducts (cholestasis) can increase pressure in the liver and make it appear stiffer than it actually is [11]. If you were experiencing a flare-up of symptoms, a bile duct infection, or a blockage when the scan was done, your score might be artificially high. Your doctor will look at this score alongside your liver enzymes and imaging to understand the full picture.
Protecting Your Liver
When your liver shows signs of advanced scarring, protecting your remaining healthy tissue becomes a top priority. While the scarring from PSC is generally not reversible, taking steps to reduce further stress on your liver can help slow progression. Your doctor will likely advise you to avoid alcohol entirely. You should also consult your care team before starting any new prescription medications, over-the-counter painkillers, or herbal supplements, as some can be difficult for a stiff liver to process.
Common questions in this guide
What does a FibroScan measure in PSC?
Is a FibroScan score over 10.5 kPa considered high?
Can my FibroScan score fluctuate or be falsely high?
Will I need an endoscopy if my FibroScan score is over 10.5?
How can I protect my liver if I have advanced scarring?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my score of 10.5 kPa align with what you are seeing in my blood work and MRI scans?
- 2.Given my FibroScan score, do I need an endoscopy to check for esophageal varices, or is my platelet count high enough to safely wait?
- 3.Could active bile duct blockages or inflammation be artificially inflating my stiffness score?
- 4.How frequently should we repeat the FibroScan or other imaging to monitor for changes?
- 5.Are there any specific medications, supplements, or lifestyle habits I should stop immediately to protect my liver?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers.
Krawczyk M, Ligocka J, Ligocki M, et al.
Scandinavian journal of gastroenterology 2017; (52(12)):1407-1412 doi:10.1080/00365521.2017.1370009.
PMID: 28851259 - 2
Quality criteria for the measurement of liver stiffness.
Boursier J, Decraecker M, Bourlière M, et al.
Clinics and research in hepatology and gastroenterology 2022; (46(1)):101761 doi:10.1016/j.clinre.2021.101761.
PMID: 34325013 - 3
The Complementary Value of Magnetic Resonance Imaging and Vibration-Controlled Transient Elastography for Risk Stratification in Primary Sclerosing Cholangitis.
Cazzagon N, Lemoinne S, El Mouhadi S, et al.
The American journal of gastroenterology 2019; (114(12)):1878-1885 doi:10.14309/ajg.0000000000000461.
PMID: 31738286 - 4
Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.
Chazouillères O, Potier P, Bouzbib C, et al.
Clinics and research in hepatology and gastroenterology 2022; (46(1)):101775 doi:10.1016/j.clinre.2021.101775.
PMID: 34332142 - 5
Validation of Transient Elastography Cut Points to Assess Advanced Liver Fibrosis in Children and Young Adults: The Boston Children's Hospital Experience.
Lee CK, Mitchell PD, Raza R, et al.
The Journal of pediatrics 2018; (198()):84-89.e2 doi:10.1016/j.jpeds.2018.02.062.
PMID: 29685617 - 6
MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes.
Bookwalter CA, Venkatesh SK, Eaton JE, et al.
Abdominal radiology (New York) 2018; (43(12)):3260-3270 doi:10.1007/s00261-018-1590-4.
PMID: 29626258 - 7
Baveno Criteria Safely Identify Patients With Compensated Advanced Chronic Liver Disease Who Can Avoid Variceal Screening Endoscopy: A Diagnostic Test Accuracy Meta-Analysis.
Szakács Z, Erőss B, Soós A, et al.
Frontiers in physiology 2019; (10()):1028 doi:10.3389/fphys.2019.01028.
PMID: 31481896 - 8
Impact on follow-up strategies in patients with primary sclerosing cholangitis.
Bergquist A, Weismüller TJ, Levy C, et al.
Liver international : official journal of the International Association for the Study of the Liver 2023; (43(1)):127-138 doi:10.1111/liv.15286.
PMID: 35535655 - 9
Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.
Catanzaro E, Gringeri E, Burra P, Gambato M
Cancers 2023; (15(20)) doi:10.3390/cancers15204947.
PMID: 37894314 - 10
Comparison of liver stiffness measurement with MRE and liver and spleen volumetry for prediction of disease severity and hepatic decompensation in patients with primary sclerosing cholangitis.
Idilman IS, Low HM, Bakhshi Z, et al.
Abdominal radiology (New York) 2020; (45(3)):701-709 doi:10.1007/s00261-019-02387-4.
PMID: 31894383 - 11
Pathogenesis, Non-Invasive Assessments and Treatment of Hepatic Fibrosis in Autoimmune Liver Diseases.
Lytvyak E, Hirschfield G, Shreekumar D, et al.
Liver international : official journal of the International Association for the Study of the Liver 2025; (45(8)):e70190 doi:10.1111/liv.70190.
PMID: 40682413
This page explains FibroScan score interpretation for Primary Sclerosing Cholangitis for educational purposes only. Your hepatologist is the best source for interpreting your specific liver stiffness results and medical imaging.
Get notified when new evidence is published on Primary sclerosing cholangitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.